Latest Regulatory News

The ASX has challenged Wellnex Life Limited over its recent shareholder announcement featuring forward-looking financial forecasts from SP Angel, prompting a mandated retraction due to disclosure shortcomings.

EVE Health Group has successfully passed all shareholder resolutions at its recent General Meeting, paving the way for its acquisition of Nextract Pty Ltd and announcing significant leadership changes.

TruScreen Limited has obtained a waiver from NZ RegCo allowing it to allot oversubscribed shares up to 10 business days after its capital raising offer closes, subject to shareholder approval. This move aims to streamline the company’s NZ$3 million placement and share purchase plan.

TruScreen Group Limited has announced a capital raising initiative involving Placement and Share Purchase Plan (SPP) Options, aiming to secure approximately NZ$3 million to fund strategic growth and working capital needs. The offer, subject to shareholder approval, includes up to 80.9 million Placement Options and 55.5 million SPP Options exercisable at A$0.02.

TruScreen Group Limited has launched a NZ$1.22 million Share Purchase Plan offering discounted shares to eligible investors, aiming to fuel growth in key international markets and public health initiatives.

TruScreen Group Limited has announced a NZ$3 million capital raise to fund strategic growth initiatives across Asia and Africa, alongside repaying existing debt. The raise includes a placement and share purchase plan with free attaching options, signaling confidence in its expanding cervical cancer screening programs.

QEM Limited's trading suspension has been lifted immediately following its announcement of a new capital raise, signaling a pivotal moment for the company’s financial strategy.

Gold Mountain Limited has issued nearly 486 million shortfall shares to underwriter Jose Luis Manzano, lifting its recent trading halt. A second tranche to Magnus Capital awaits shareholder approval, marking a pivotal step in the company’s capital raising.

The ACCC has issued a preliminary Statement of Issues regarding Elders Limited’s proposed acquisition of Delta Agribusiness, signaling potential competition challenges that could affect the deal’s timeline.

Uvre has cleared a crucial regulatory hurdle in its acquisition of New Zealand’s Waitekauri Gold Project, setting the stage for new leadership and exploration activities.

The ACCC has raised preliminary concerns that Elders’ proposed acquisition of Delta Agribusiness could reduce competition in rural merchandise supply across key Australian regions, potentially impacting prices and service quality.

Clarity Pharmaceuticals has successfully imaged the first patient in its pivotal Phase III AMPLIFY trial for Cu-SAR-bisPSMA, a next-generation diagnostic agent targeting recurrent prostate cancer. This milestone sets the stage for potential FDA approval and broader clinical adoption.